1.88
price down icon2.59%   -0.05
after-market After Hours: 1.87 -0.010 -0.53%
loading
Werewolf Therapeutics Inc stock is traded at $1.88, with a volume of 8.08M. It is down -2.59% in the last 24 hours and up +41.35% over the past month. Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
See More
Previous Close:
$1.93
Open:
$2.13
24h Volume:
8.08M
Relative Volume:
13.84
Market Cap:
$85.97M
Revenue:
$19.94M
Net Income/Loss:
$-37.37M
P/E Ratio:
-1.8077
EPS:
-1.04
Net Cash Flow:
$-33.38M
1W Performance:
-3.59%
1M Performance:
+41.35%
6M Performance:
+198.37%
1Y Performance:
-0.53%
1-Day Range:
Value
$1.82
$2.13
1-Week Range:
Value
$1.7843
$2.15
52-Week Range:
Value
$0.595
$4.18

Werewolf Therapeutics Inc Stock (HOWL) Company Profile

Name
Name
Werewolf Therapeutics Inc
Name
Phone
617-952-0555
Name
Address
200 TALCOTT AVENUE, WATERTOWN
Name
Employee
46
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
HOWL's Discussions on Twitter

Compare HOWL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
HOWL
Werewolf Therapeutics Inc
1.88 88.26M 19.94M -37.37M -33.38M -1.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
421.15 105.19B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
450.68 60.24B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.86 61.82B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
798.94 49.09B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
351.09 37.52B 4.56B -176.77M 225.30M -1.7177

Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-03-24 Initiated JMP Securities Mkt Outperform
Aug-24-23 Initiated Wedbush Outperform
Jun-06-23 Resumed Jefferies Buy
Sep-10-21 Initiated BofA Securities Buy
May-25-21 Initiated Evercore ISI Outperform
May-25-21 Initiated H.C. Wainwright Buy
May-25-21 Initiated Jefferies Buy
May-25-21 Initiated SVB Leerink Outperform
View All

Werewolf Therapeutics Inc Stock (HOWL) Latest News

pulisher
09:18 AM

Werewolf Therapeutics Says Investigational Melanoma Therapy WTX-124 Receives US FDA Fast Track Designation - MarketScreener

09:18 AM
pulisher
08:30 AM

Werewolf Therapeutics receives FDA Fast Track for melanoma therapy By Investing.com - Investing.com Canada

08:30 AM
pulisher
08:10 AM

Werewolf Therapeutics receives fast track designation from the U.S. FDA for WTX-124, an investigational therapy for the treatment of cancer - MarketScreener

08:10 AM
pulisher
08:09 AM

Werewolf Therapeutics Receives Fast Track Designation from - GlobeNewswire

08:09 AM
pulisher
08:00 AM

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer - Stock Titan

08:00 AM
pulisher
Oct 06, 2025

Werewolf Therapeutics Faces Nasdaq Compliance Challenge - TipRanks

Oct 06, 2025
pulisher
Oct 06, 2025

Werewolf Therapeutics notifies Nasdaq of audit committee noncompliance after board member’s passing - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Using flow based indicators on Werewolf Therapeutics Inc.Market Growth Summary & Risk Managed Trade Strategies - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Will earnings trigger a reversal in Werewolf Therapeutics Inc.2025 Institutional Moves & Long-Term Safe Investment Ideas - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Werewolf Therapeutics Inc. stock chart pattern explainedWeekly Trade Report & AI Enhanced Trade Execution Alerts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Intraday pattern recognizer results for Werewolf Therapeutics Inc.Fed Meeting & Weekly High Return Stock Forecasts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Will Werewolf Therapeutics Inc. stock maintain dividend yieldJuly 2025 Short Interest & Verified High Yield Trade Plans - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

Jefferies Initiates Werewolf Therapeutics(HOWL.US) With Buy Rating, Announces Target Price $4 - 富途牛牛

Oct 04, 2025
pulisher
Oct 03, 2025

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - GlobeNewswire

Oct 03, 2025
pulisher
Oct 03, 2025

Werewolf Therapeutics to Present Innovative Research at SITC 40th Annual Meeting - Quiver Quantitative

Oct 03, 2025
pulisher
Oct 03, 2025

3 Posters: Werewolf Therapeutics to Present WTX-124, mWTX-330 Research at SITC Nov 5-9 - Stock Titan

Oct 03, 2025
pulisher
Sep 30, 2025

Published on: 2025-09-30 05:19:05 - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Goldman Sachs Group Inc. Has $109,000 Stock Holdings in Werewolf Therapeutics, Inc. $HOWL - Defense World

Sep 30, 2025
pulisher
Sep 30, 2025

Published on: 2025-09-30 01:50:53 - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

What analysts say about Werewolf Therapeutics Inc stockMomentum Trading Signals & Outstanding Growth Stocks - earlytimes.in

Sep 29, 2025
pulisher
Sep 28, 2025

Earnings visualization tools for Werewolf Therapeutics Inc.Portfolio Performance Summary & Fast Moving Stock Trade Plans - newser.com

Sep 28, 2025
pulisher
Sep 26, 2025

What institutional flow reveals about Werewolf Therapeutics Inc.Market Risk Analysis & Risk Controlled Swing Alerts - newser.com

Sep 26, 2025

Werewolf Therapeutics Inc Stock (HOWL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Werewolf Therapeutics Inc Stock (HOWL) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
RA CAPITAL MANAGEMENT, L.P.
Director
May 14 '25
Buy
0.98
162,539
159,288
6,237,482
RA CAPITAL MANAGEMENT, L.P.
Director
May 13 '25
Buy
0.98
52,974
51,915
6,074,943
MPM BioVentures 2014, L.P.
10% Owner
Mar 27 '25
Sale
1.05
1,963
2,061
3,208,793
EVNIN LUKE
Director
Mar 27 '25
Sale
1.05
2,425
2,546
4,309,860
GADICKE ANSBERT
10% Owner
Mar 27 '25
Sale
1.05
4,386
4,605
6,718,670
$85.38
price down icon 2.05%
$23.34
price up icon 4.71%
$32.74
price up icon 0.31%
$106.28
price up icon 0.21%
$161.81
price down icon 0.31%
biotechnology ONC
$351.09
price up icon 2.77%
Cap:     |  Volume (24h):